n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of n-3 PUFAs in addition to amiodarone and renin-angiotensin-aldosterone system (RAAS) inhibitors on the maintenance of sinus rhythm after electrical conversion in patients with persistent Atrial fibrillation (AF).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Azienda Ospedaliera Spedali Civili di Brescia; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
• Treatments: Amiodarone

Criteria

Inclusion Criteria:

• persistent Atrial Fibrillation (AF) lasting > one month

• history of at least one AF relapse after previous electrical or Pharmacological cardioversion

Exclusion Criteria:

• left atrium size > 6 cm

• severe valvulopathy

• myocardial infarction during the previous 6 months

• unstable angina

• NYHA heart failure class IV or hemodynamic instability

• cardiac surgery during the previous 3 months

• significant pulmonary thyroid and hepatic disease

• contraindications to treatment with amiodarone or RASS inhibitors

• chronic renal dysfunction

• QT > 480 msec in the absence of bundle-branch block

• bradycardia < 50 b/min

• diagnosis of paroxysmal AF

• hyperkalemia

• pregnancy

• any disease or other medical treatment that, in the opinion of the investigators, could interfere with the study.